Efficacy Comparison of Xalatan and Azopt on POAG and OH
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Prostaglandin analogs (PGAs) represent a new class of active ocular hypotensive agents and possess a unique mechanism of action. Many studies suggested that 0.005% Latanoprost was more effective and safer than other anti-glaucoma medications, such as beta-blockers. It has also been found to be more effective than other class of anti-glaucoma medications such as carbonic anhydrase inhibitors and alpha agonists. However data on such comparison is lacking in Chinese patients. So it is necessary to increase China experience and get clinical data from China. Besides latanoprost, brinzolamide is known as one of the other ocular hypotensive agents with less systemic adverse effects, therefore it is selected as the controlled medication of this study. The administration phase will be 4 weeks because it is long enough to compare both efficacy and safety of the study drugs and accounting for following-up conditions in China, it will be easier for the investigators to get enough subjects in a limited stage if the observation time is shorter.
Before treatment with the study drugs, any previous glaucoma drugs will be washed out. The minimum washout periods are 5 days for cholinergic agonists, 1 week for adrenergic agonists, 3 weeks for adrenergic β receptor blockers and 4 weeks for PGAS. After washout, the patients will be randomised send to two parallel study groups: one group will receive latanoprost 0.005% once daily in the evening, the other group receive 1.0% Brinzolamide twice daily. Randomization will be obtained using a list of random numbers .During the study there will be four visits: screening, baseline, 2 weeks, and 4 weeks of treatment. The IOP will be measured with a Goldmann tonometer at 8 am for each visit. The tonometry will be performed before the administration of the dose of the day in patients treated with Brinzolamide. Three separate measurements will be taken for each eye and the mean of the three measurements will be used in the statistical analysis. Best corrected visual acuity and refraction will be determined and a slit lamp examination, ophthalmoscopy will be performed at all visits.
| Condition | Intervention |
|---|---|
|
Ocular Hypertension |
Drug: Latanoprost Drug: Brinzolamide |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Comparison of the Effects of Latanoprost(0.005%) and Brinzolamide(1.0%) on Intraocular Pressure in Primary Open-angle Glaucoma and Ocular Hypertension |
- Intraocular Pressure [ Time Frame: Baseline, 2 weeks, 4 weeks ] [ Designated as safety issue: No ]Three separate measurements will be taken for each eye. And mean result will be taken if the difference between measurements is within 2 mmHg , or use the median if the difference between measurements is greater than 3 mmHg.
| Enrollment: | 130 |
| Study Start Date: | February 2010 |
| Estimated Study Completion Date: | December 2010 |
| Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: latnoprost
once daily
|
Drug: Latanoprost
once daily
|
|
Active Comparator: Brinzolamide
two times daily
|
Drug: Brinzolamide
Two times daily
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosed with POAG or OHT
- Older than 18 years, either sex
- With IOP≤30mmHg in both eyes and with IOP>21mmHg in either eye after washout
- Understand the study instructions and are willing to attend at all follow-up appointments
- Be willing to comply with study medication use
- Ready for written informed consent
Exclusion Criteria:
- Visual field defects within the central 10°
- Absence of vision in one eye
- History of hypersensitivity to any components of the study medications
- Contraindications to carbonic anhydrase inhibitors or prostaglandins
- History of ocular herpetic disease, uveitis, or cystoid macular edema
- Ocular history of trauma, inflammation, surgery or use of corticosteroids (within 2 months)
- History of ocular laser therapy within 3 months
- Severe dry eyes
- Signs of ocular infection, except blepharitis
- Corneal abnormality that may affect IOP measurements
- Unwilling to accept the risk for hyperchromia of the iris or development of hypertrichosis
- Pregnant females or lactating mothers
Contacts and Locations More Information
No publications provided
| Responsible Party: | Yingzi PAN/Professor of Ophthalmological Department, Peking University First Hospital |
| ClinicalTrials.gov Identifier: | NCT01084902 History of Changes |
| Other Study ID Numbers: | PKU1H001, PKU1H |
| Study First Received: | March 10, 2010 |
| Last Updated: | March 10, 2010 |
| Health Authority: | China: Food and Drug Administration |
Keywords provided by Peking University First Hospital:
|
POAG OH Xalatan Azopt Primary Open Angle Study |
Additional relevant MeSH terms:
|
Hypertension Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Latanoprost Brinzolamide |
Antihypertensive Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 13, 2013